Exodus Point Capital Management, LP Pyxis Oncology, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.06 - $5.58 $76,242 - $139,031	24,916 Added 27.85%	114,387 $379,000
Q1 2024 May 14, 2024	SELL	$2.03 - $6.59 $660,970 - $2.15 Million	-325,601 Reduced 78.44%	89,471 $381,000
Q3 2023 Nov 09, 2023	BUY	$1.6 - $2.78 $248,817 - $432,320	155,511 Added 59.91%	415,072 $826,000
Q2 2023 Aug 10, 2023	BUY	$2.46 - $4.07 $466,320 - $771,513	189,561 Added 270.8%	259,561 $664,000
Q1 2023 May 11, 2023	BUY	$1.38 - $6.0 $96,599 - $420,000	70,000 New	70,000 $281,000
Q1 2022 May 13, 2022	SELL	$4.04 - $11.43 $1.01 Million - $2.85 Million	-249,762 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$8.39 - $13.64 $2.1 Million - $3.41 Million	249,762 New	249,762 $2.74 Million

101

28.2M

539K

54.1K

Ticker PYXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,096,400
Market Cap $59.3M
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.